Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.
Lue webcast- ja audiocast-lähetysten transkriptejä
Lue webcast- ja audiocast-lähetysten transkriptejä
Huomio: Tämä on koneellisesti luotu transkripti ja se saattaa sisältää epätarkkuuksia.
Good afternoon, and welcome to Revenio Group Q4 2023 Earnings Call. My name is Jouni Toijala, Group CEO, and with me here today. We also have our CFO, Robin Pulkkinen, in. The agenda for today is that I'll start by going through the highlights of Q4, including a short summary of financials. Then also the same for 2023. So overall business highlights, plus high-level financial performance. Then Robin is going to do the deep dive to the numbers. And then we are going to go through the changes in shareholder structure plus the financial guidance for 2024. So let's start with the Q4 business highlight. So the quarter went exactly as we expected it to go. So if we first start from the tonometry side of the business. So, strong sales for iCare IC200 tonometer, including the probe's imaging device sales, especially iCare DRSplus, plus iCare ILLUME with the ultrawide field function. Sales growth was strong for Q4. And then, if you look at the overall progress on the screening side of the business. So referring to our portfolio, so also good uptake on the eye care side. And if looking at the gross margin, looking at the EBIT, so good performance also on profitability level. So if you look at the numbers, so net sales up 3.1% up to the 29.1 million. Robin is going to cover the currency exchange rate part. But for Q4, not major impact on that one EBIT €9.5 million, up 1.6%. And then cash flow, slightly or quite significantly lower compared to the previous year. But we closed a couple of big deals. So this is due to the accounts receivable. So Robin is going to cover on that one. So nothing to be worried about EPS. Up to $0.27 up from $0.21. So if moving back to full on 2023. So a couple of highlights here. So as you recall, we renewed the organizational structure. February 1st, 2023. So that has been a good decision for us. And everything is up and running really well. So if you remember, we structured the sales out from the product management and marketing. Then we included all product management organization functions in one organization. Same for the R&D. So that change has been going really well, then on the screening side, we have been launching a new iCare ILLUME. So now we have the AMD, we have also glaucoma. And then we closed the OphthAI partnership for the iCare ILLUME and then also new product releases. Couple of those. So iCare IC200 tonometer quick measure. Then we also launched new software version for the compass perimeters. And the sales of the compass picked up quite well also during the Q4 then on the positive note, end of last year, we also received the regulatory approval for iCare DRSplus in China. So we have been applying that one for a really long time. But finally, we got everything sorted out before Christmas. So that's a really good thing. Then a couple of big deals during the end of Q4, one in Germany and one in the USA related to the iCare DRSplus and also in the USA, also the iCare IC200. And then, as of end of November, we also held the CMD and gave financial guidance for the long-term growth target. Plus then we updated slightly the strategy in terms of the numbers. So net sales for the full year 96.6 million slightly down if we take the currency adjusted number. So we had the growth, 2.2% and then EBIT down. Then from 29.7 to 26.3. So roughly 10% or a bit more than 10%, Robin is going to cover the cash flow part and the overall earnings per share, €0.7 down from €0.8. But with these words, over to you, Robin.
Thank you. So a bit more details on the numbers. Like Jouni covered, 3.1% growth in the last quarter of the year. There was no impact on the last quarter. But for the whole year, looking at the whole year sales almost at the same level as last year, reported sales is actually down by 0.4%. Also, the gross margin rather stable, within the quarter and full year. Well, actually, the whole year is down, 1.3%. But when you look at the impact, during the last couple of years there, actually last year, the FX, there was a headwind, for €1.6 million for us compared to 2022, there's a tailwind for €6 million. So it's actually a quite big impact on our numbers. In the last quarter we didn't have any non-recurring costs, but for the whole year we incurred 1 million, non-recurring costs for certain one-time projects. So when you look at the quarterly numbers, the reported and the adjusted are the same numbers. But for the whole year, the adjusted EBIT is actually, 28.3 million, 27.3 million and 28.3% of sales. The EBIT percentage is down 2.3%. Um, if you look at the gross margin, it's down 1.3%. So, the biggest part of that is actually the gross margin that has brought down the profitability. Also, the OpEx is impacting 41%. Um, the year-end was extremely good. Um, considering that, like we discussed earlier, we didn't have the microperimeter products in our portfolio this year. So we ran out of stock. Um, and we've been catching up that gap in Q3 and Q4. Uh, looking at the trend line. Um, Q1 and Q4 are pretty much on the trend line as we've seen in earlier years. But as we know, the second and third quarter were below the trend. And that has been the challenge for us for the whole year. Uh, the Q4 sales performance is actually quite good when you leave out the macroperimeters. So there was double-digit growth for the main products that we had in the portfolio that we could sell. Uh, it's double-digit, actually closer to 15 than to ten. Uh, so a quite good finish for the year. Also, the profitability for the last quarter was the highest we've had so far, 9.5 million. Um, basically, more than one-third of the profitability for the whole year was generated in the last quarter. Um, there are a few reasons. Basically, the sales mix, but also the operating costs increased during the whole year quite moderately. So for the whole year, our OpEx is up 3.3% year over year. Uh, so there you can see the scalable business model going also in the other direction. Uh, not only when we grow, but also when we have had a tougher time on the top line. We've also been able to scale the costs. Uh, most of that is actually, as we discussed earlier, the variable bonus payments are quite low for last year. So, that is one driver for the higher profitability. Uh, looking at this year. Maybe that's something that, if we assume that we keep our guidance, the bonus pool is definitely going to be a lot bigger than last year. Um, but also, as we've discussed earlier, the iCare DRSplus and iCare ILLUME FDA clinical trials are ongoing, and we have the new media coming out with the clinical trials. So we'll have more clinical trial costs in our P&L this year, which is something just to keep in mind going forward. So it's something that actually goes through the P&L and we don't put it on the balance sheet. So it's going to be impacting the profitability this year. Uh, but the good thing is it's a one-time cost. So to say, well, they will go away then the following year. Uh, cash flow. Um, so the Q4 wasn't as good as we would have hoped. Um, but of course, there's maybe a good reason for that. So we did have a really good end of the year. Uh, the AR increased significantly. Uh, so due to these larger deals and overall, uh, we had finished extremely well. And then, of course, the Q4 sales are significantly higher than the Q3 sales. So, so, uh, the AR did go up. And that's the main reason why the cash flow, operating cash flow was, was lower in Q4, for the whole year, we also saw working capital changes and then the, uh, certain tax payments in Q2 that partly related to earlier years, uh, was the other reason why the operating cash flow didn't develop as favorably as we've seen before. But I'm sure, uh, Q1 hopefully will be better. Then maybe it'll turn to the other direction when we collect the money. That is outstanding. Um, balance sheet remains very strong. Um, the equity ratio is again at its highest. That's been, uh, so 72.7% net gearing. Uh, -3.6. So we have 21.5 million in the bank at the end of the year. And then interest-bearing debt of, uh, a little bit under 18 million. So the net debt position is -3.6 million. Uh, that we have at the end of the year. Um, the board will propose to the AGM, um, that we will pay a dividend of $0.38 per share. Uh, that roughly adds up to slightly above 10 million. On the shareholders, there's actually, uh, very little change. Surprisingly, it's not often that it's so stable. Um, basically the Finnish ownership has gone down by 0.4%. Um, and basically all the ten names on the list are pretty much the same, but maybe one or 2 have changed, uh, positions or places. So, so nothing much to report here. And then for the guidance, revenue group's exchange rate, adjusted net sales are estimated to grow 5 to 10% from the previous year, and profitability, excluding non-recurring items, is estimated to remain at a good level. And then we're good for questions. Yeah.
Thank you, Robin. Uh, let's move to the question part.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Nico Kangas from SEB. Please go ahead.
Hello, this is Nico from SEB. I have a couple of questions and I'll go one by one. So, uh, first of all, your sales growth improved from Q2 and Q3 quarter. Much so, uh, you earlier had slower demand from PE-driven optimistic clients. So did these sales come back or did your sales improve in other segments?
Hey. Hi, Nico. Thank you for the questions. Um. Uh, we were able to, uh, find a new client. So. So optometry and in general ophthalmology. So that was the reason for the growth.
All right. Thanks. And, uh, overall, if we think about your development. So Q4 has been traditionally quite big quarters for you. So, uh, how do you see the market, uh, in Q4 and maybe going into 2024? So did you see the market improving or was this. Improvement in your sales growth. Only. Only, uh, gaining market share.
So if we, if we go back to last year. So the, the Q2 was the most difficult for us. And then we, we were able to start turning the dial during the Q3. And then as you can see of course, during the Q4 and if we look to reach and so the USA selling well and then Europe selling and growing, uh, pretty well. Uh, APAC uh, more or less the stable. So I think that it, it, it's uh, it there has been a positive improvement uh, also on on kind of from the, from the overall from the, the market perspective in general, I think. But I mean, we have really good products which, which are extremely competitive. So. So I think that has helped us a lot during the Q4. But do you have anything to drop in on this one?
Yeah, I think April was the most challenging month probably ever for the company last year. So I think since then, the development has been positive, quarter after quarter and month after month. So, of course, going into this year, I think the comparables for Q1 are quite challenging. But we're quite optimistic that in Q2 and Q3, we should be reaching nice growth levels again and for the whole year to reach the guidance of 5 to 10%. So I think the sales team is also fully behind that guidance.
All right, I understand. So, would you describe that the market environment is currently at least a little bit easier compared to maybe six months ago or?
I would say certainly more favorable than Q2 last year. Okay.
Thanks. Then about the bigger deals you mentioned. So, cool to indicate. At least some kind of ballpark. That's how big of an impact did it have in Q4, and how much should we expect? 24 and 25.
So we had, yeah, there were a couple of deals that were seven digits in size, but still a lot lower than the year earlier. So, nothing to compare to that. But the good thing is that they're not fully delivered. So we're going to be delivering against those agreements hopefully for this year and maybe even next year, some, but we don't have any kind of solid orders yet for the year. But there's a good outlook that they should continue. At what level and at what stage is still open?
Yeah, I understand. Then, on the costs. So you mentioned the clinical trials that will lead to increased costs this year. So, how many clinical trials were there in 2023? I mean, how much more is coming now in 2024?
That was very little last year. So we're talking about in percentages. It's a huge increase. But we're talking about probably above a million.
Yeah, right.
So, somewhere around 1.5 to 2 million, if I have to guess. So it's more than a €1.5 million increase.
Okay. So a 1.5 million increase in 2024.
Yeah, yeah. But then not everything. It's not done. We don't know all the details for all the major trials, for example. But that's if you have to forecast or model something, if you use 1.5 to 1.8 or 2 million somewhere around there, probably, it's going to be the cost increase.
And I think the one concrete addition compared to the normal run rate is the FDA approval and the clinical studies, for iCare DRSplus plus the iCare ILLUME. So that's roughly a bit more than a million or between 1 and 1.5 million.
All right. I understand.
Thanks. I think.
Going back. So, of course, that's a kind of one-off. So not visible then in 2025.
Yeah, yeah, I understand. And then one final question from me. So you say that there was a good pickup in sales. So is there any kind of significant level that we could be seeing that in your sales in Q4 already or?
I would say that the percentages are looking good, but we start from such a small base. So, on that front, not moving the needle but the trend is looking good and the level of interest is looking good. And I think this applies in general for the screening-related cases. Because if we go for these bigger deals, the deals. So they actually went to the screening and not in the traditional use cases where our clients are using our devices. So we have a competitive product which is iCare DRSplus for the forthcoming screening-related client cases. So that's a really good thing and we are happy for that.
All right, I understand. That helps. Thanks. I guess that's all from me.
Thank you. Thanks.
The next question comes from Daniel Chepstow from Danske Bank. Please go ahead.
Mr. Chepstow from Danske Bank. Uh.
I have a few questions as well. Maybe going back to that discussion on the margins and the margin guidance. You noted that this would be remaining on a good level. But maybe, still going back to the topic on the clinical trial costs. I guess you said that there would be a one and a half to two million headwind from these trials this year. So I guess, uh, quite a quick and dirty look at the cost base and so on, including the bonuses as well. Coming this year, margin expansion with even 5 to 10% sales growth could be quite a tough ask. Uh, what's your view on this?
Yeah, it's hard to cover for one-time costs. Uh, it's, uh, we don't have any specific rabbits in the hat to cover for those, so it's really something that is going to hit this year, the profitability. And we didn't have it last year. But we typically have clinical costs, often on and off. Um, like for the earlier releases as well. So this is part of the business. And if you want to do deals or business in the US, we need to do the trials. So there's not really much we can do about it.
Of course, helping the long-term growth. So that's that, for sure.
It won't help this year. Sales might be low, but it's a cost or investment for the future growth.
Yes, absolutely. Thanks. Um, maybe then on the sort of product launches, uh, maybe on the micro perimeter. Can you remind us when the winning occurred? Exactly. This year, we're looking to launch the new product.
For Micro Perimeter. Am I the new version of that? We are targeting Q4 for that one.
Okay. So that won't have any sort of additional contribution to the growth outlook if it's only for Q4.
Uh, uh, let's have a C on that one because, uh, we. So, if you had a product, we would essentially have orders placed. So, the goal is actually to have something to ship already during Q4. So, we'll start collecting orders in some states for sure.
Okay, that's clear. Um, maybe on the next topic, I guess, on the FDA approval for the iCare ILLUME, I guess I am assuming this is the combination you will use to get the FDA approval on the fast track you have discussed. So what's the status on that one? As you will be doing clinical trials and so on, I guess, any news on that this year would be a kind of tight schedule.
Or if you have fully invested in that one. So, clinical trials. We have been working on the pre-submission for FDA already. So, in good shape on that one. Then, based on the feedback we receive. We have to run the clinical studies and then do the application based on the clinical study results. So for sure I'm pretty sure that we won't have the approval for 2024. So it's going to be first half of 2025 at the earliest, hopefully Q1, but remains to be seen.
All right. That's clear. I guess my final question, maybe on the home tonometry product, you know that. Okay. You submitted some applications for the reimbursement on the planned schedule. What's the next step here? When are you expecting to get an answer on whether you will get full or partial reimbursement for the product?
Yeah. So the procedure goes with all the glaucoma specialists in the USA, we did the documentation. We passed the application on time for the so-called HCPCS, which is the Healthcare Common Procedure Coding System. So that goes to the so-called CMS, which is the Centers for Medicare and Medicaid Services. So the documentation is in and then we are waiting for feedback early Q4, from the CMS. Are the codes going to be received or not? And then at the same time and after that, we start the discussions between the payers or the insurance companies and so forth. So, hopefully, we advise on Q4 related to codes and then the final reimbursement in early 2025. So that's the schedule and procedure, how it goes.
All right. That's very clear. Thanks for the answers.
Thank you. Thanks.
The next question comes from Patrik Sjöberg from Carnegie Investment Bank. Please go ahead.
Hello, Jouni and Robin. Thank you for the presentation. Uh, I've still got a couple of clarifying questions. First, with regards to your guide, sales guidance for 2024. Earlier, you talked about a weak H1. But if my understanding is now correct, you're no longer referring to a weak Q1, other than saying that the Q1 comparables were, uh, hard.
Yeah, I think. Well, hopefully, we will see how the interest starts to perform. But, uh, the expectation has been that they will start to go down, which will help then like the PE driven optometry. Um, but yeah, definitely, I think that Q1 is challenging due to the comparables. Then, of course, we have easier comparables in Q2, but I think in general, we have certain new product launches coming out that will be supporting and helping the second half more than the first half. So that's also one reason behind the thinking there. But I think in general, the economy and interest rates were one driver for those comments earlier.
So I would say, right, Robin? So, no change from the earlier comment and view related to the first half. So we see the second half, then, in a way, in a better light, when it comes to growth.
All right. Thanks. And still a clarification on the expected launch for the new iCare ILLUME. So, your sales guidance as of now includes some expectation of the microperimeters supporting your sales in H2.
Uh, actually not too much more.
Upside, I think that part.
Yeah. Um.
Some, but if it's zero, it doesn't really change the guidance.
All right. Okay, thanks. Then, another question relates to these bigger orders you mentioned in the release. And I'm particularly interested in understanding the demand for the iCare DRSplus for screening purposes in Germany. So, first of all, is this solution now sold with iCare ILLUME, or is this excluding the iCare ILLUME offering?
Uh, that's, uh, only the DRSplus deal. So, so. Okay, so if you go back to the strategy. So we have a twofold strategy. So we want to maximize the device business as well. So if there's a combination or if there's a demand for screening solutions which require an extremely good camera, but then the client has decided that they don't need, or they use as an example human triaging in the screening solution and not AI-assisted. So for sure, we want to sell the best device for the purpose. And that's another part of the strategy. And this is linking to that part. And then of course the other part is the doctors plus the loan plus the AI. But to sum up, sorry to be long here, but this was the iCare DRSplus sale only.
Okay. Thanks. And what kind of or what type of client are we talking about? And does this kind of shed some new light on the potential in the European market? I mean, can we draw any broader conclusion about the demand for screening solutions without AI?
So.
So, I think we don't fully want to disclose the type of the client, but went for the client segment where we are already operating and where we have a strong position. And then the other segment where we have been especially selling during 2023, the loan plus the iCare DRSplus plus the AI. So those are going to the non-traditional segments like diabetic clinics and so forth where we are not currently operating. But this bit more bigger deal, which we closed during the Q4. So that went to our existing client base.
All right. Um. Then maybe you mean. Yeah. You mentioned China during the presentation. And the market approval there. So with this, what kind of sales efforts are you now doing in China and what kind of sales potential do you see in China for this year?
So if you go back in time, back for a long, long time. So, at the time of the interview when we had the so-called doctors. So that was a product before the iCare DRSplus. So, we had the China approval for the doctors, the fundus imaging camera, that device went to its end of life. And of course, during the same time, for China, we had the tonometry approvals. So we have been continuing selling the tonometry in China. But then now we have the iCare DRSplus approval for China, which we received during the Q4 last year, which is of course extremely good because now we have a competitive imaging product for China. As for the sales strategy, sales potential in China. Related to sales strategy. So, we established a sales office and we have a small team now in China. And we have been working towards closing the distributors in China during the second half of last year. And now, of course, we have even the product for them to sell starting from Q1. I won't go into the numbers we have budgeted and planned for China. But again, that if we are really able to get the sales up. So that's a nice, nice upside for us also for 2024.
Okay. Thanks. And, then finally, just to clarify, the extra or one-time costs for 2022, 2024. So, can you still quantify what you now have seen out. So higher clinical costs, higher bonus accruals? Are we talking in total about 3 million, for 2024. Um.
So looking at 2023, our salary costs, actually, the personnel costs came down, if I recall, right, a little bit more than 1%. We didn't even hire some people during last year, so I kind of. I wouldn't give you an exact number how much the bonuses are, but they are in the millions, the whole pool. So depending on what the payout is or what the performance is. So it's anything between like zero and 4 million depending on what the performance is. But in that range and then the clinical trials, but for last year the bonus pool was very small and not there. Not even everybody received it. So.
All right. Okay. Thank you. That's all for me. Thank you.
Thank you. Pam.
The next question comes from Johnny Sandoval from Nordica. Please go ahead.
Yeah.
Thanks. It's from Claudia. Thanks for the presentation. Maybe I have a question related to how you expect the growth to be divided between imaging devices and tonometers in 2024. And, what should we expect from the gross margin?
I could comment a bit. Perhaps the product mix, then Robin perhaps comments on the gross margin part. So I think the same trend is going to continue also during 2024. So if you go back to 2022-2023 as well. So constantly defined, the imaging business has been growing faster than the tonometry business. Uh, and I think that's a relevant expectation for 2024 as well. And if you look at the growth drivers on the tonometry side, the iCare IC200 tonometer is growing nicely because of the new features. What we introduced, the probes, are growing nicely, at home, as before. Growing nicely. Then, if you go for fundus imaging, the iCare DRSplus is one growth driver, adding an ultra-wide field growth driver. Then we introduced the iCare ILLUME new software version 4.0.0. So, that has been selling well during Q4, expected to sell well this year as well. And then we have a microperimeter coming. So those are more or less the growth drivers. And of course, the some tailwind also related to the screening solutions side of the business. So I think the revenue mix is perhaps the one thing to keep in mind. And that leads perhaps to Robin related to cross-matching.
We haven't disclosed exactly what the different product line gross margins are. But if you go back before the interview, like the revenue group, gross margins were even up to 80, 85%, when we acquired Sentry there, around 62. We've been able to, of course, like we've discussed earlier, improve the imaging business gross margins over the years now, but it's still, still like the gross margins on the tonometry side are extremely good. On the device side especially, so I don't think the imaging device gross margins will probably never reach that same level. Just simply the weight of a tonometer. There is a couple hundred grams and the weight of imaging devices, I don't know, 20 kilos. So there's simply there's so much more technology and hardware in there that reaching the similar gross margin levels is probably not doable. In the coming years at least. So, in a way, it will be lowering the gross margin, the higher imaging growth. But then hopefully the software solutions in the screening will start to help in improving it in a couple of years.
Okay. Thanks. That's clear. I think we went through the merger quite well, but, I think, Robin, you mentioned that there would be some other products also coming online in H2. So can you give any indication as to what we should expect during 2024? In addition to my.
We spend 10% of our revenue on R&D. So there's new stuff cooking all the time. So hopefully we'll get something out this year. I don't know if anyone wants to come and comment. No, no.
Not too much. But I mean, uh, plenty of work going into the new products. So nothing else to comment. Unfortunately, at this stage.
Okay.
That's clear.
Uh, yeah.
Sure. Thanks. And then, uh, lastly on the M&A side, I think you have been screening the market all the time. So how is the market looking when considering the, uh, valuation levels currently? And, uh, have you found something interesting in the market?
I think we still have a slight mismatch between the valuation expectations that the targets would like to have compared to what we would like to pay. And I think that still remains the main challenge. But would you agree on this one? So, constantly working on the different opportunities but that's still the case.
There are very attractive targets. But the valuation, I think, is the challenging side. Um, for us now.
Okay. Thanks. That's all for me.
The next question comes from Parachain Sammy from Carnegie Investment Bank. Please go ahead.
Hi. Thanks for taking my question. Uh, a small and short one. Uh, with regards to the good demand you've seen in, uh, in respect to the economy. Uh, do you know if that's driven by replacement demand or, uh, new clients?
I mean, that's hard. That's hard to say for sure. Uh, for sure. Both. So if you go, uh, go back in time. So we still have quite a lot of these original so-called TT01. So if you recall the original tonometers from ten, then, then, then 15 years back. So they are still working really well and the clients are using and certain clients start to do the replacement. So that's one part. And of course, there's still an untapped market for handheld tonometers still in the world. And we have to remember that the iCare IC200 tonometer, that's the only tonometer in the world which is able to measure in a supine position. So, that's a unique feature. And now combined with the quick measurement mode. So that's also the one reason that in certain cases our clients want to measure in supine or inclined positions. And that's the only device which is able to do that.
Okay. Thanks. And then another question came to my mind with regards to the different regions. Do you usually give an indication of which of your markets have performed? Well and, and which maybe have been quieter? And can you give a recap on Q4 so which markets were good and which maybe quieter.
Yeah. The US, performing really well as always during Q4, Europe, performing and growing really well, the APAC more stable. But growing.
Okay.
All right. Okay, that's all for me. Thank you.
There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
I think we are done. Thank you very much for the interest and for all the good questions and I hope you are going to have a good spring and we are here soon again. Thank you. Thank you.



















